Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Prevnar 13
Biotech
Pfizer's 20-valent pneumococcal vaccine hits goal in infants
After four doses, all 20 serotypes met the statistical noninferiority criteria in a study that compared the candidate to Prevnar 13.
Nick Paul Taylor
Aug 12, 2022 8:00am
Merck's rival to Pfizer's Prevnar 13 hits goal in phase 3 again
Oct 20, 2020 8:55am
Affinivax banks $120M for vaccines against hospital superbugs
Apr 23, 2020 7:00am
